Abstract: Methods and systems for protecting websites from cross-site scripting are disclosed. A request for a web page comprising a web page element is received from a client. It is determined if the web page comprises a data integrity token for the web page element. It is also determined if a value of the data integrity token matches an expected value. If the web page comprises the data integrity token and if the value matches the expected value, the web page comprising the web page element is sent to the client. If the web page does not comprise the data integrity token or if the value does not match the expected value, a protective operation is performed.

Abstract: Disclosed are various embodiments for automated service interface optimization. In one embodiment, a service client and/or a service provider is reconfigured to use an optimized version of a data transfer interface, where the optimized version transfers fewer data items from the service provider to the service client. In another embodiment, service calls from a service client for multiple different data objects are aggregated into an aggregated service call for a data object. In yet another embodiment, an optimized data object is provided to a service client in response to a request for an unoptimized data object. If the service client attempts to use a data item excluded from the optimized data object, the excluded data item is then provided to the service client.

Abstract: Inhibitors of saporin-L1 are disclosed, as are related compositions and uses thereof, in particular in cancer therapy that employs saporin-L1-linked immunotoxins.

Abstract: The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

Abstract: Disclosed are various embodiments for automated service interface optimization. A service client sends a request for a data object to a service provider. The service client receives an optimized version of the data object from the service provider in response to the request. The optimized version of the data object has been optimized to exclude one or more data items based at least in part on data object usage metrics associated with the service client.

Abstract: The present invention provides a system and method for fail-safe call survival by detecting failure of an active call serving component and switching the service over to a standby component. The system and method will prevent an existing call, whether established or to be established, from being dropped due to a single point of failure within a Voice over Internet Protocol system. The continuation of the call is based on the failed component as opposed to relying on communication endpoints to re-initiate or re-route the failed call. Call recovery is initiated independent from the call path of a call. The detection of a condition or need for call recovery and the determination to initiate call recovery procedures are made without involving endpoints or intermediate points of the call. The availability and sanity of all components are continuously monitored and are tailored specifically for the duties of each component.

Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.

Abstract: Disclosed are various embodiments for automated service interface optimization. A plurality of usage metrics for at least one service client corresponding to a set of data items within a data object are determined in at least one computing device. The data object is obtainable by at least one service client from a service provider. The service provider is configured to provide an optimized data object to the at least one service client. The optimized data object includes a proper subset of the set of data items. The proper subset is determined based at least in part on the usage metrics.

Abstract: A method is provided for conducting electrolysis at or below 1.23 V. The method comprises filling an electrolysis reactor having an aluminum anode and a copper cathode with a sufficient amount of solution such that at least a portion of the anode and the cathode are immersed in the solution; the solution comprising water, an electrolyte and a catalyst; and applying a voltage across the reactor of less than or equal to 1.23 V. The solution is comprised of water, aluminum sulfate and an ammonium salt. The method allows for total gas to be produced at a rate in excess of the theoretical maximum 1.06 l/min at a current of 93 amps.

Abstract: Embodiments of a closed-contact electroplating cup assembly that may be rapidly cleaned while an electroplating system is on-line are disclosed. One disclosed embodiment comprises a cup assembly and a cone assembly, wherein the cup assembly comprises a cup bottom comprising an opening, a seal surrounding the opening, an electrical contact structure comprising a plurality of electrical contacts disposed around the opening, and an interior cup side that is tapered inwardly in along an axial direction of the cup from a cup top toward the cup bottom.

Abstract: This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.

Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

Abstract: Using a complex emulsion for treating a subterranean formation, such as to dissolve minerals therein (e.g. carbonates, scales, and/or filter cake) to improve permeability, substantially improves post treatment fluid clean-up for improved hydrocarbon production. The complex emulsion is made by mixing an acid aqueous phase with an oil external microemulsion to give an initial product, where the acid aqueous phase is an external phase and the microemulsion is an internal phase. Then the initial product is mixed with a second oil (e.g. xylene, diesel, toluene, kerosene, other aromatics, refined hydrocarbons and the like) containing an emulsifier to make a complex emulsion.

Abstract: Disclosed are azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds.

Abstract: Method and compositions and kits for isolation, identification, and quantification of miRNAs and other small RNAs, including but not limited to, siRNAs, mRNAs, and snRNAs are disclosed. Methods of diagnosing a disease or its progression are also disclosed.

Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

Abstract: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.

Abstract: Changing concentrations of brine in a gravel pack carrier fluid gelled with a viscoelastic surfactant (VES) increases the fluid efficiency for gravel packing long interval wells, such as wellbore producing interval greater than about 100 feet (about 30 m). VES-gelled fluids used as gravel packing fluids herein also include surfactants, fluid loss control agents, internal breakers and brine in addition to the grave. The viscoelasticity of fluid system can suspend and deliver high concentration of the gravels while reducing carrier fluid volume.

Abstract: A process is disclosed for preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (I), or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (Ia) involving, as a key step, the enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone compound of formula (II).